Two Doses of Pfizer Covid-19 Vaccine Provides 95% Protection: Israel National Data
The first national-level observational assessment of the effectiveness of Pfizer-BioNTech Covid-19 vaccine in Israel has found that two doses provide more than 95% protection against coronavirus. Published in The Lancet, the national data highlights that two doses of the Pfizer-BioNTech vaccine are 95% efficacious in protecting against covid-19 infection, hospitalisation, severe illness as well as death, including among the elder people.
Israel comes across as the first country worldwide to report national data on the Pfizer-BioNTech vaccine. It must be noted that a single dose was associated with 58% protection against infection, 76% against hospitalisation, and 77% against death, emphasising the significance of fully vaccinating adults.
The analysis also sheds light, for the first time, on the public health benefits of a national vaccination programme, which led to a decline in Covid-19 infections in Israel. As per the Israel Ministry of Health, the country has provided a unique real-world opportunity to determine the effectiveness of the vaccine and to observe wider effects of the vaccination programme on public health. Furthermore, as of now, no country across the globe had described the national public health impact of a nationwide Covid-19 vaccination campaign.
It must be noted that Pfizer-BioNTech vaccine for coronavirus is not registered in India. At present, the pharmaceutical giant is preparing $70 million worth of drug supplies to India, including steroids, antibiotics, and anticoagulants.
Currently, Pfizer is in talks with the Indian government to gain expedited approval for its Covid-19 vaccine.
Read More
Things to Know About a COVID-19 Vaccine
Things to Know About Life After Recovering From COVID-19
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.
